Qiqi Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qiqi Wan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Yinqin Hu
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, China
3 shared publications - Yongming Liu
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
3 shared publications - Zhaohui Xu
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, China
3 shared publications - Jiahui Yang
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, China
2 shared publications - Cheng Lu
Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, China
1 shared publication Jiahui Yang
1 shared publication
Latest Publications
- Open Access
- 8 June 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (4) , 1164-1176
Hypertensive heart disease mortality trends attributable to high body mass index over the period 1990-2021 and projections up to 2040
Introduction: This study aimed to evaluate trends in HHD mortality attributable to HBMI from 1990 to 2021 and projections up to 2040.Material and methods: Data on HHD mortality attributable to HBMI were obtained from the Global Burden of Diseases (GBD) 2021 database. Temporal trends in the burden of HHD attributable to HBMI were analyzed using generalized linear models to calculate the estimated annual percentage change (EAPC) in age-standardized mortality rates (ASMR) and age-standardized disability-adjusted life-years (DALYs) rates (ASDR) from 1990 to 2021.Results: From 1990 to 2021, the global ASMR for HHD attributable to HBMI increased from 6.83 (4.37 - 9.32) to 7.21 (4.23 - 9.94), with an EAPC value of 0.33 (0.27 - 0.39) for the ASMR. the ASDR increased from 144.72 (106.21 - 182.76) to 147.33 ( 109.06 - 183.45) with an EAPC value of 0.15 (0.1 - 0.21) for ASDR. Particularly severe ASMR and ASDR were observed in most countries in Africa and in a few countries along the Mediterranean coast. In contrast, most developed countries in North America, Europe, and Australia presented lower ASMR and ASDR. When the overall trend was divided into subsections, at the end of the study period, ASMR and ASDR for HHD attributable to HBMI showed a downward trend. By dividing the regions by SDI, middle SDI had the greatest fluctuation in ASMR and ASDR, and low SDI showed an increasing trend in ASMR and ASDR at the final joinpoint.Conclusions: Therefore, more targeted prevention approaches should be established to mitigate this growing trend.
- 8 June 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (4) , 1164-1176
Open AccessHypertensive heart disease mortality trends attributable to high body mass index over the period 1990-2021 and projections up to 2040
Introduction: This study aimed to evaluate trends in HHD mortality attributable to HBMI from 1990 to 2021 and projections up to 2040.Material and methods: Data on HHD mortality attributable to HBMI were obtained from the Global Burden of Diseases (GBD) 2021 database. Temporal trends in the burden of HHD attributable to HBMI were analyzed using generalized linear models to calculate the estimated annual percentage change (EAPC) in age-standardized mortality rates (ASMR) and age-standardized disability-adjusted life-years (DALYs) rates (ASDR) from 1990 to 2021.Results: From 1990 to 2021, the global ASMR for HHD attributable to HBMI increased from 6.83 (4.37 - 9.32) to 7.21 (4.23 - 9.94), with an EAPC value of 0.33 (0.27 - 0.39) for the ASMR. the ASDR increased from 144.72 (106.21 - 182.76) to 147.33 ( 109.06 - 183.45) with an EAPC value of 0.15 (0.1 - 0.21) for ASDR. Particularly severe ASMR and ASDR were observed in most countries in Africa and in a few countries along the Mediterranean coast. In contrast, most developed countries in North America, Europe, and Australia presented lower ASMR and ASDR. When the overall trend was divided into subsections, at the end of the study period, ASMR and ASDR for HHD attributable to HBMI showed a downward trend. By dividing the regions by SDI, middle SDI had the greatest fluctuation in ASMR and ASDR, and low SDI showed an increasing trend in ASMR and ASDR at the final joinpoint.Conclusions: Therefore, more targeted prevention approaches should be established to mitigate this growing trend.
- 21 May 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (2) , 882-891
AI-enhanced computational discovery of promising ALK5 inhibitors in a ultra-large chemical space library for cardiovascular Disease therapy
Cardiac fibrosis, characterized by excessive extracellular matrix deposition, is a critical contributor to cardiovascular diseases, including heart failure. Transforming growth factor-beta 1 signaling, especially through activin receptor-like kinase 5 (ALK5), plays a key role in cardiac fibroblast activation and fibrosis. Traditional drug discovery approaches face challenges in identifying ALK5 inhibitors. This study leverages computational methods to expedite the discovery of potential ALK5 inhibitors. An active learning model was trained to screen a vast compound library, resulting in the selection of promising candidates. Molecular fingerprint clustering analysis and the absorption, distribution, metabolism, excretion, toxicity evaluation further characterized these compounds. Machine learning-based quantitative structure - activity relationship models predicted their activity. Molecular dynamics simulations assessed binding stability in different environments. DE50349483 and DE21377883 emerged as promising candidates with potential inhibitory effects. This study showcases the power of computational methods in drug discovery, offering hope for innovative therapies in cardiac fibrosis.
- 21 May 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (2) , 882-891
AI-enhanced computational discovery of promising ALK5 inhibitors in a ultra-large chemical space library for cardiovascular Disease therapy
Cardiac fibrosis, characterized by excessive extracellular matrix deposition, is a critical contributor to cardiovascular diseases, including heart failure. Transforming growth factor-beta 1 signaling, especially through activin receptor-like kinase 5 (ALK5), plays a key role in cardiac fibroblast activation and fibrosis. Traditional drug discovery approaches face challenges in identifying ALK5 inhibitors. This study leverages computational methods to expedite the discovery of potential ALK5 inhibitors. An active learning model was trained to screen a vast compound library, resulting in the selection of promising candidates. Molecular fingerprint clustering analysis and the absorption, distribution, metabolism, excretion, toxicity evaluation further characterized these compounds. Machine learning-based quantitative structure - activity relationship models predicted their activity. Molecular dynamics simulations assessed binding stability in different environments. DE50349483 and DE21377883 emerged as promising candidates with potential inhibitory effects. This study showcases the power of computational methods in drug discovery, offering hope for innovative therapies in cardiac fibrosis.
- 22 April 2024
- Published by S. Karger AG in Cardiology
- p. 1-19
The Efficacy of Machine Learning Models for Predicting the Prognosis of Heart Failure: A Systematic Review and Meta-Analysis
Introduction: Heart failure (HF) is a major global public health concern. The application of machine learning (ML) to identify individuals at high risk and enable early intervention is a promising approach for improving HF prognosis. We aim to systematically evaluate the performance and value of ML models for predicting HF prognosis. Methods: PubMed, Web of Science, Scopus, and Embase online databases were searched up to April 30, 2023, to identify studies on the use of ML models to predict HF prognosis. HF prognosis primarily encompasses readmission and mortality. The meta-analysis was conducted by MedCalc software. Subgroup analyses include grouping based on types of ML models, time intervals, sample sizes, the number of predictive variables, validation methods, whether to conduct hyperparameter optimization and calibration, data set partitioning methods. Results: A total of 31 studies were included. The most common ML models were random forest, boosting, support vector machine, neural network. The area under the receiver operating characteristic curve (AUC) for predicting HF readmission was 0.675 (95% CI: 0.651–0.699, p < 0.001), and the AUC for predicting HF mortality was 0.790 (95% CI: 0.765–0.816, p < 0.001). Subgroup analyses revealed that models with the prediction time interval of 1 year, sample sizes ≥10,000, the number of predictive variables ≥100, external validation, hyperparameter tuning, calibration adjustment, and data set partitioning using 10-fold cross-validation exhibited favorable performance within their respective subgroups. Conclusion: The performance of ML models in predicting HF readmission is relatively poor, while its performance in predicting HF mortality is moderate. The quality of the relevant studies is generally low, it is essential to enhance the predictive capabilities of ML models through targeted improvements in practical applications.
- 22 April 2024
- Published by S. Karger AG in Cardiology
- p. 1-19
The Efficacy of Machine Learning Models for Predicting the Prognosis of Heart Failure: A Systematic Review and Meta-Analysis
Introduction: Heart failure (HF) is a major global public health concern. The application of machine learning (ML) to identify individuals at high risk and enable early intervention is a promising approach for improving HF prognosis. We aim to systematically evaluate the performance and value of ML models for predicting HF prognosis. Methods: PubMed, Web of Science, Scopus, and Embase online databases were searched up to April 30, 2023, to identify studies on the use of ML models to predict HF prognosis. HF prognosis primarily encompasses readmission and mortality. The meta-analysis was conducted by MedCalc software. Subgroup analyses include grouping based on types of ML models, time intervals, sample sizes, the number of predictive variables, validation methods, whether to conduct hyperparameter optimization and calibration, data set partitioning methods. Results: A total of 31 studies were included. The most common ML models were random forest, boosting, support vector machine, neural network. The area under the receiver operating characteristic curve (AUC) for predicting HF readmission was 0.675 (95% CI: 0.651–0.699, p < 0.001), and the AUC for predicting HF mortality was 0.790 (95% CI: 0.765–0.816, p < 0.001). Subgroup analyses revealed that models with the prediction time interval of 1 year, sample sizes ≥10,000, the number of predictive variables ≥100, external validation, hyperparameter tuning, calibration adjustment, and data set partitioning using 10-fold cross-validation exhibited favorable performance within their respective subgroups. Conclusion: The performance of ML models in predicting HF readmission is relatively poor, while its performance in predicting HF mortality is moderate. The quality of the relevant studies is generally low, it is essential to enhance the predictive capabilities of ML models through targeted improvements in practical applications.